IGF1 and cancer: A need for clinical implementation of a GHRH-Ant arose from the inability of somatostatin analogs to lower GH and IGF-1 levels sufficiently enough to inhibit the growth and progression of IGF-dependent cancers, as well as a growing body of evidence painting GHRH as a pleiotropic autocrine growth factor [44–46], apart from its role in the pituitary [6, 7].